Steven Bulera, Corporate Vice President, Chief Scientific Officer: Safety Assessment, Charles River Laboratories, explores various use-cases of AI in improving drug discovery. It’s difficult, if not impossible, to escape the headlines and… Read More
CN Bio has introduced two new animal microphysiological system (MPS) models to its contract research services (CRS) that it hopes will enhance translatability in preclinical drug safety and toxicology assessments. Building upon its drug induced liver injury (DILI) assay, the company says the expanded offering enables rapid,… Read More
Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone. MT: ERG has been considered ‘undruggable’ for decades. Why is this? JH: ERG… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
A new event ‘Principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro’ is now open for registrations. The webinar, hosted by DDW and supported by bit.bio, will take place on 3 December 2024 at 4pm GMT. In his talk,… Read More
In this webinar hosted by DDW and supported by bit.bio, Dr Stephen Ferguson, Investigator, Mechanistic Toxicology, Division of Translational Toxicology (DTT), National Institute of Environmental Health Sciences, explores the complexities of in vitro modelling for human liver toxicity and pharmacology. He discusses the development… Read More
A new Case Study is now available to download for free: ‘In Vivo Evaluation Of Bispecific-Cell Engager Efficacy & Safety‘. Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing… Read More
Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In… Read More
Around 30% of drugs show adverse reactions during human clinical trials despite promising pre-clinical studies. One of the major causes of the high attrition rate is the poor predictive value of current preclinical models used in drug development. Traditional 2D cell cultures often fail to replicate the cellular… Read More
The global ADME toxicology testing market is predicted to generate a revenue of $19.21 billion by 2030, with a growth rate of 10.2%. Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies… Read More
Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug… Read More
Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug… Read More
Jeffrey Fisher, PhD, Senior Research Fellow at ScitoVation, has been awarded the 2022 Society of Toxicology Arnold J. Lehman Award for his career-long body of work on physiologically based pharmacokinetic (PBPK) and biologically based dose response (BBDR) modeling tools to improve risk assessment. Fisher’s accomplishments … Read More
Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox. Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of… Read More
